Economy

Investment Research Analysts Opinion: Forterra, Inc. (FRTA), Arrowhead Pharmaceuticals, Inc. (ARWR)

The Lower end of the earnings estimate is $-0.24, while the higher end of the earnings estimate is $-0.07.

Many analysts are providing their Estimated Earnings analysis for Arrowhead Pharmaceuticals, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.1/share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 3rd. They expect $-0.13 EPS, up 58.06% or $0.18 from last year's $-0.31 per share. The difference between the expected and actual EPS was $0.07/share, which represents an Earnings surprise of 50%. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 3.00, which implies that analysts are generally neutral in their outlook for ARWR over the next year.

Arrowhead Pharmaceuticals, (NASDAQ:ARWR) gapped up before the market opened on early Tue. the share had previously closed at $3.34, but started trading at $3.43. The company earned $4.37 million during the quarter, compared to analyst estimates of $13.24 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/09/12/arrowhead-pharmaceuticals-inc-arwr-rating-increased-to-sell-at-valuengine.html.

ARWR is now overvalued by 135.33% relative to the average 1-year price target of $1.50 taken from a group of Wall Street Analysts. Lastly, Jefferies reissued a "hold" recommendation and fixed a $2.00 price objective on the stock of Arrowhead Pharmaceuticals in a note on Fri, Aug 4th. The stock has "Hold" rating by Cantor Fitzgerald on Wednesday, November 30. Jefferies Group now has a "Hold" rating and a $2.00 target price on the stock.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded up 0.29% during mid-day trading on Tuesday, reaching $3.44. Institutional investors own 20.63% of the company's stock. Analysts have placed a $1.5 price target on Arrowhead Pharmaceuticals, Inc., suggesting a -56.27% decline from recent close. Trading volume was up 200.48% over the stocks average daily volume.

The volume of the particular stock is the shares bought and sold in a single trading day. Wells Fargo & Company MN lifted its stake in shares of Arrowhead Pharmaceuticals by 144.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 53,500 shares in the last quarter. Bank of Montreal Can raised its position in shares of Arrowhead Pharmaceuticals by 4,355.8% in the third quarter. Moors & Cabot Inc. raised its position in shares of Arrowhead Pharmaceuticals by 11.0% in the third quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company's stock valued at $186,000 after purchasing an additional 74,776 shares in the last quarter. Virtu KCG Holdings LLC lifted its position in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings has an ownership of 99,267 stocks of the biotechnology firms shares valued $161,000 following acquiring an extra 53,215 stocks in the previous period.

This company has been competing with others in the Healthcare space and offers its own combination of interesting factors Arrowhead Pharmaceuticals, Inc. "(ARWR) Given Average Recommendation of "Hold" by Analysts" was originally published by StockNewsTimes and is the sole property of of StockNewsTimes.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company.



Like this

Latest


19 September 2017
Minnesota teen's death at NDSU dorm under investigation
Delaney had reportedly been spending the weekend with a friend on the seventh floor of Sevrinson Hall at NDSU. NDSU Police say they found an unresponsive 17-year-old boy at Sevrinson Hall just after noon Sunday.

19 September 2017
RBI Considering to Introduce its Own Cryptocurrency Similar to Bitcoin
CBOE Holdings Inc has applied with USA regulators to handle a bitcoin futures contract and an exchange-traded fund. CEO Nobuyuki Hirano spoke with CNBC during an appearance at a conference in Singapore.

19 September 2017
WWE Starrcade Live Event Announced for November
Also on the bill are The Hardy Boyz , who are from the RAW brand, but are making a special appearance in their home state. This will be SmackDown Live-exclusive, and a WWE Network Special Event similar to the first Roadblock in March of 2016.

18 September 2017
Dawood Ibrahim's brother Iqbal Kaskar arrested for extortion in Mumbai
Summary: Mumbai: Dawood Ibrahim's brother Iqbal Kaskar was picked up by Thane anti-extortion cell in an ongoing case of extortion. A police official not willing to be quoted said Kaskar was wanted for an extortion case recently lodged against him.

18 September 2017
Oracle Corporation (NYSE:ORCL) Climbs 0.31% Pre-market Trade
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $218.38B. Finally, BerganKDV Wealth Management LLC boosted its stake in shares of Oracle Corporation by 2.3% in the second quarter.

18 September 2017
Fosun to acquire Gland Pharma, with smaller stake
Raju, will remain on the Gland board and the current management team will continue to run the company. Fosun Pharma shares yesterday jumped as much as 4.3 percent in Shanghai.

18 September 2017
Gorakhpur child deaths: Owner of oxygen supplying firm held
He was declared an absconder on September 15 by the anti-corruption court and orders were issued to attach his various properties. There were allegations that the deaths were caused by a disruption in the oxygen supply over unpaid bills.

18 September 2017
Kaiser Aluminum Corp. (KALU) EPS Estimated At $1.11
On July 21 Bank of America left the stock rating at "Underperform" but moved down the price target from $92.00 to $85.00. Gifford Craig E sold $15,576 worth of stock or 300 shares. 29,449 shares were sold by Parker P.W., worth $1.53 million.

18 September 2017
Pfizer, Inc. (PFE) Given a $37.00 Price Target at Jefferies Group LLC
The rating was upgraded by Goldman Sachs to "Neutral" on Wednesday, September 16. (NYSE:PFE) rating on Tuesday, December 1. Hudson Valley Advisors Adv holds 1.66% or 173,011 shares. 1,428 were accumulated by Northwestern Mutual Wealth Management.

18 September 2017
Paychex, Inc. (PAYX) Analysts See $0.60 EPS; Xerium Technologies Has 0.81 Sentiment
Triangle Securities Wealth Management bought 4,330 shares as the company's stock declined 1.76% while stock markets rallied. Tributary Capital Management Limited Liability Company owns 0.34% invested in Paychex, Inc. (NASDAQ:PAYX) for 4,690 shares.



Recommended